UBS cuts Teva's price target again
UBS gives two scenarios for Teva's share: an upside, in which the target price reaches $17, and a downside in which the target price drops to $1.
Israeli bitcoin holders take on banks
A freedom of information petition has been filed demanding that the banks reveal their policies on accounts for proceeds of cryptocurrency trading.
Wix market cap overtakes Teva
Although Teva's share price rose 4.06% on Wall Street on Friday, the Israeli pharmaceutical company's market cap still finished the week below the fast-growing DIY website company.
CPI down in July
Israel's Consumer Price Index fell 0.3% last month, with housing prices nearing their 2017 peak.
Cellcom loss widens
The company reported a tough quarter with a NIS 35 million loss, following a NIS 15 million loss in the preceding quarter and a NIS 35 million loss in the fourth quarter of 2018.
US Congress heaps more misery on Teva
Teva fell over 10% on a bearish Wall Street after Congress members accused it of obstructing a price-fixing probe and Moody's revised its outlook to negative.